About 1 in 2 cancer patients are eligible for immunotherapy (with a PD1 antibody) but only 1 in 5 respond

One reason is immune system aging: immunosenescence

But senolytics - which eliminate aged cells - can strengthen immunotherapy (in mice, here, then a clinical trial)

There’s more on our page: (breakingground.substack…) based on the trial (nature.com/articles/s41…)